Randomized, Double-blind, Placebo-controlled Study for the Assessment of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics, of Multiple Oral Doses of GLPG0634 in Japanese and Caucasian Healthy Subjects

Trial Profile

Randomized, Double-blind, Placebo-controlled Study for the Assessment of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics, of Multiple Oral Doses of GLPG0634 in Japanese and Caucasian Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Nov 2015

At a glance

  • Drugs Filgotinib (Primary)
  • Indications Crohn's disease; Rheumatoid arthritis
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Galapagos NV
  • Most Recent Events

    • 08 Nov 2015 Results will be presented at the American College of Rheumatology (ACR) Annual Meeting 2015, according to a Galapagos NV media release.
    • 13 Jun 2015 Results presented at the 16th Annual Congress of the European League Against Rheumatism (n = 20).
    • 15 Sep 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top